Poziotinib failed to meet its primary endpoint (ORR 14.8%), but induced tumor reduction in 65% of NSCLC patients with EGFR exon 20 insertion mutants in a phase II trial [46]. Here, EGFR is linked to non-small cell lung carcinoma.